Biologics: the Quest for a Universal Antidote

2009 . Flight

R R et al et embe Oney, S. Oney, , 1224–1228 1224–1228 , C 2CVTKEM/QTICP e 15

| Monica Hoyos Monica Nature Med. Nature Volume 8 Volume ORIGINAL RESEARCH PAPER RESEARCH ORIGINAL Development of universal antidotes to control control to antidotes universal of Development activity. aptamer (2009) the safety profile of aptamer-based aptamer-based of profile safety the encourage might and therapeutics range wider a for development their indications. of ch highlights ch - R -

ed eserv Resea ed. All rights r s Limit Several polymers were found found were polymers Several typethis of safety the Although in clinical studies, the possibility possibility the studies, clinical in aptamers, to antidotes designing of and sequence their of regardless enhance subtantially could structure, these two aptamers with more favour more with aptamers two these which protamine, than properties able effectssuch adverse with associated is bloodpressure. in fall sudden a as effectsof the reverse completely to potency their and aptamers, these their with correlated antidotes as of Two aptamers. the for affinity β-cyclodextrin- — polymers these and (CDP) polycation containing polymer polyphosphoramidate rapidly to able were — (PPA-DPA) effects anticoagulant the neutralize blood, whole in aptamers various of sequence- are they that suggesting Furthermore, antidotes. independent sequential that showed authors the anticoagulant an of administration forma the to led CDP and aptamer complex aptamer–polymer an of tion and rapidly CDP pigs, In mice. in at for and minutes 5 (within durably effectsthe reversed minutes) 60 least clotting activated on aptamer the of toxicity. of signs any without time tested further be to have will agent of and factor Xa) could both beboth could Xa) factor and This protamine. by inactivated examine further to them prompted antidote single a that possibility the the counteract and to bind might They severalaptamers. of activity small or DNA of screen a out carried to polymers delivery RNA interfering nucleic-acid-binding other identify to antidotes provide that molecules ublisher

aptamer.

agulants and for conditions conditions for and agulants The authors observed that two two that observed authors The Previous studies with antico with studies Previous Aptamers are small single- small are Aptamers BIOLOGIC Nature MedicineNature customized oligonucleotides is pro is oligonucleotides customized the addition, In expensive. hibitively complex aptamer–antidote resulting response, immune an trigger could adverse the exacerbate might which the effectof that aptamers anticoagulant primarysequences, different had in targets and structures secondary IXa (factor cascade coagulation the to vascular endothelial growth factor factor growth vascularendothelial to age-related for approved been has However, degeneration. macular developed being also are aptamers antico as and cancer as such that shown have aptamers agulant sequences oligonucleotide customized form to aptamers with pair base that activity. aptamer prevent RNAs duplex approach viable a not is this However, clinical many for antidotes generate to such developing as applications be used to combat bleeding due to to due bleeding combat to used be anticoagulant the of administration design rational the However, heparin. costly, and challenging is antidotes of most for available not are they so Reporting therapeutics. approved in describeantidote colleagues moleculeswholea for class of aptamers. basedthoseon — drugs that molecules nucleic-acid stranded targets. protein inhibit and bind binds that drug aptamer one far, So The quest for a universal antidote universal a for quest The to way direct a provide Antidotes of effects adverse acute counteract can protamine example, for drug; a Drug Discovery

S ew VI e R e R u NAT